Navigation Links
Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
Date:2/5/2008

NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) today announced preliminary results of a Phase III study of memantine HCl (currently marketed as Namenda(R), a twice-daily immediate- release formulation) in a novel once-daily formulation. The study evaluated the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg memantine extended-release, once-daily formulation compared to placebo in outpatients with moderate to severe Alzheimer's disease currently treated with a cholinesterase inhibitor. The results indicate that patients treated with memantine 28 mg extended-release formulation experienced statistically significant benefits in cognition and clinical global status compared to placebo. Additional data from the study are expected to be presented later in the year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

The recommended dose for Namenda is currently 10 mg two times a day (20 mg/day), or for patients with severe renal impairment 5 mg twice a day (10 mg/day). Patients in this study were titrated to 28 mg/day in a once-daily modified release formulation. Namenda is currently available in tablets or liquid form.

"The higher dosage and once-daily formulation will provide patients with the efficacy and tolerability expected from Namenda, in a more convenient once-daily form," said Ivan Gergel, M.D., Senior Vice President of Scientific Affairs at Forest Laboratories and President of the Forest Research Institute. "Based on the results of this study, Forest plans to pursue a new drug application for the memantine extended-release once-daily formulation."

About t
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
2. Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
3. Forest Laboratories Lexapro and Generics-Dominated Fluoxetine Lead First-Line Therapy in the Treatment for Major Depression
4. Nanotube forests grown on silicon chips for future computers, electronics
5. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
6. BioSpace Launches 3rd Edition of BioForest(TM) Bioscience Marketing Campaign
7. Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
8. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
10. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...mbassador to also Visit Detroit , ...vid Appia, French Ambassador for International Inv...nce Agency, , , , ,What: Ambassador Appia is avai...iness initiatives adopted by France to further dev...for innovation and development., , ,When: Availabl...
(Date:11/24/2009)...ov. 24 Sigma-Aldrich Cor...e NASDAQ OMX conference on Tuesday, December 1st a...d parties may listen via live audio broadcast over...ig m a a ldrich.com/ . Users can click the "... Sigma-Aldrich: Sigma-Aldrich is a leading Life ...
(Date:11/24/2009)...AI, Nov. 24 /PRNewswire-Asia/ -- Shanghai Biolaxy ...stration (SFDA) has approved the,investigational n...ject,(Nodlin), an innovative insulin formulation t... to initiate its first phase I clinical study. ,...igh blood glucose and poor,metabolism. The complic...
(Date:11/24/2009)...vember 24 Shire plc (LSE...harmaceutical company, today,announced that it has...for,velaglucerase alfa, the company,s enzyme repla... Type 1 Gaucher disease. This is the third marketi...n submitted, with previous,submissions in the Unit...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
..., April 20 Bionovo, Inc. (Nasdaq: BNVI ) today ...new data on the nature of the active compound and ...g candidate, BN108. The presentation is being made...n of Cancer Research (AACR) in Denver, today. , ,... , , , BN108, an aqueous extract of Anem...
...ned Physicians Join World Class Group of Advisors ... today announced the expansion of its Clinical Adv...SA, and G. Ralph Corey, MD, as the sixth and seven...leaders. Dr. Batts is a Professor of Medicine at ...tious Diseases at its Kalamazoo Campus. Dr. Corey...
...,s largest independent dermatology company, acquir..., New global business will have combined revenues ...ct pipeline , , Significant step forward to grow ...new revenue and synergy opportunities , , LONDON,...Stiefel Laboratories Inc. today announced that the...
Other Biology Technology:Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 2Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 2GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 3GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business 4
(Date:11/25/2009)... may be used to boost resistance to, or slow, the ... Medicine researchers report in a study published .... , Parkinson,s disease is caused by a degenerat... known as the substantia nigra, which is responsib... dopamine in late-stage Parkinson,s causes symptom...
(Date:11/25/2009)...ers and ambulance workers faced a terrifying rescu...attled to save people from the collapsing Twin Tow...cuated as many people as they could in an area whi...g their jobs even harder was the problem of poor c...ves jammed mobile networks with calls and the emer...
(Date:11/25/2009)... linchpin of the environment, where atmosphere, bi...students see soil as "just dirt" a place to grow ...re challenged with the task of helping students an...soil in the environment. , A collaborative proj...University of Nebraska-Lincoln, Oregon State Unive...
Breaking Biology News(10 mins):Hormone ghrelin can boost resistance to Parkinson's disease 2Magic box for mission impossible 2Magic box for mission impossible 3It's not just dirt! 2Morpace Reports 3A H1N1 Flu Could Adversely Impact Holiday Shopping Season 60094 1Morpace Reports 3A H1N1 Flu Could Adversely Impact Holiday Shopping Season 60094 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 1Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 2Rcadia Medical Imaging Wins 2009 AuntMinnie com Best New Radiology Vendor Award 5701 3Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 1Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 2Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 3Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 4Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 5Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 6Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 7Shire Presents Results of Five Lialda 28R 29 28mesalamine 29 Analyses at ACG 2009 Annual Scientific Meeting 5697 8
....C. -- A new study led by Duke University research...cially those that had been converted into farm fie...ersity. , But that,s a good thing, say the study...nd soils, natural conditions. , "It sounds counte...wetlands, decreased soil bacterial diversity repre...
...nd downs of Greenland,s ice sheet , Studies have...g, likely because of increasing average summer air...stigate the total loss of the ice sheet,s mass fro...eters: ice discharge, which is obtained from remot...ich is derived from a model of melting ice and sno...
...s from the universities of Leicester and Cambridge...shed new research in the journal Geology this mo... year old mystery. , The 500 million year-old fos...er a century ago, still provide one of the most re...he beautiful silvery fossils show the true nature ...
Other Biology News:Shifts in soil bacterial populations linked to wetland restoration success 2Shifts in soil bacterial populations linked to wetland restoration success 3AGU journal highlights: Nov. 11, 2008 2AGU journal highlights: Nov. 11, 2008 3AGU journal highlights: Nov. 11, 2008 4AGU journal highlights: Nov. 11, 2008 5AGU journal highlights: Nov. 11, 2008 6AGU journal highlights: Nov. 11, 2008 7AGU journal highlights: Nov. 11, 2008 8AGU journal highlights: Nov. 11, 2008 9AGU journal highlights: Nov. 11, 2008 10Deep heat solution to 500-million year mystery 2
Anti-Echovirus LIGHT DIAGNOSTICS Antibody, Unconjugated from CHEMICON
Mouse Anti-JNK, phospho (Thr183 / Thr185) Antibody, Unconjugated from Raybiotech, Inc.
Goat Anti-gamma chain Polyclonal Antibody, HRP Conjugated from Exalpha Biologicals, Inc.
Rabbit Anti-Human ZFP91 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: